GlassScriptPhysician profile
Veronica Zoleta
NPI 1992446868
$2,000.43
in general payments reported to CMS, 2019-2025
16 companies · $467 in 2025
The $467 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $283 · 2023: $661 · 2024: $590 · 2025: $467.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,704 · Gift: $13.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,703.90 |
| Gift | $13.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $329.06 | 2022-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $205.84 | 2022-2025 | Xifaxan |
| Glaxosmithkline, LLC. | $195.90 | 2022-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Novo Nordisk INC | $190.90 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $173.63 | 2023-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $150.67 | 2023-2024 | Evenity, Prolia |
| Merck Sharp & Dohme LLC | $131.72 | 2022-2025 | Gardasil 9, Capvaxive, Gardasil |
| Ascend Therapeutics US, LLC | $128.10 | 2023 | |
| Currax Pharmaceuticals LLC | $117.93 | 2024-2025 | Contrave |
| Abbvie INC. | $110.85 | 2024-2025 | |
| Qol Medical, LLC | $69.09 | 2025 | Sucraid |
| Exact Sciences Corporation | $65.69 | 2023-2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $52.33 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $49.51 | 2022-2023 | Livalo, Seglentis |
| Bausch Health US, LLC | $22.45 | 2023 | Aplenzin |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $6.76 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Zoleta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.